{"id":936572,"date":"2026-02-12T08:35:26","date_gmt":"2026-02-12T13:35:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update\/"},"modified":"2026-02-12T08:35:26","modified_gmt":"2026-02-12T13:35:26","slug":"benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update\/","title":{"rendered":"Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update"},"content":{"rendered":"
\n

–The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b\/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301-<\/em><\/p>\n

\n -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint-<\/em>\n <\/p>\n

\n – An update on the Interim clinical results for Cohort 2 is planned for mid-2026-<\/em>\n <\/p>\n

\n -FDA meeting to formalize the pivotal BB-301 study design expected mid-year-<\/em>\n <\/p>\n

HAYWARD, Calif.,, Feb. 12, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (\u201cBenitec\u201d or the \u201cCompany\u201d), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary \u201cSilence and Replace\u201d DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission.<\/p>\n

\u201cWe continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,\u201d said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. \u201cWe look forward to engaging with the U.S. Food and Drug Administration (FDA) in mid-2026 to confirm the BB-301 pivotal study design and continuing to present interim clinical results at future medical conferences. I want to sincerely thank our investigators, our clinical advisors, and\u2014most importantly\u2014the patients and families who have made this progress possible.\u201d<\/p>\n

The recent and upcoming key milestones related to the development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia, are outlined below:<\/p>\n

\n
\n Responder Analysis for Study Completers<\/u>
\n <\/strong>\n <\/p>\n